Liposarcoma clinical trials report from VPA Research provides comprehensive analysis and trends in global Liposarcoma disease clinical trials. The research work analyzes the evolution of Liposarcoma clinical trial trends across countries and regions.
The report focuses on drugs and therapies being evaluated for Liposarcoma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.
Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Liposarcoma clinical trials.
Scope of the Report- - Number of Liposarcoma clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas - Trial information by Phase and Subjects recruited - Trial information by status, type, sponsor type - Drugs used for treatment of Liposarcoma - Both observational and interventional trials analyzed - Success rates of trials are analyzed - Trends in enrollment over the past ten years identified - Leading sponsors of Liposarcoma clinical trials worldwide are listed
Reasons to Buy - Track competition and design competitive advantages - Identify right partners to associate with for further research - Evaluate potential opportunities available in further clinical trials of the disease - Formulate business development strategies through success rates of clinical trials - Identify quick markets for recruiting subjects based on trials count by each market
Liposarcoma is one of the most common sub-types of soft tissue sarcoma. The sub-types vary from a local tumor to highly malignant one.
Subtypes- - Atypical lipomatous tumor (ALT) and well-differentiated liposarcoma (WDLS)- represents a locally aggressive tumor - Myxoid round cell liposarcoma (MRCL) - These tumors may have a hypercellular round cell component that signifies worse prognosis. - Pleomorphic liposarcoma- is high-grade subtype, with 34–45% risk of local recurrence and 32–57% risk of metastatic disease.
Some of the Major Developments in the recent past include- - FDA approves Eribulin Mesylate to show survival benefit in liposarcoma - Selinexor (KPT-330) for Dedifferentiated Liposarcoma - Approval of olaratumab Offers hope for Sarcoma Cancer Patients - Both existing and emerging immunotherapy treatments Likely to be successful for sarcomas
Our reports have been used by over 10K customers, including:
110 pages •
By Infiniti Research Limited
• Oct 2018
About Diffuse Large B-Cell Lymphoma DLBCL is a cancer of B-lymphocytes. It is the most common type of NHL among adults. It is an aggressive (fast-growing), complex, and difficult-to-treat form of NHL, which refers to a group of cancers of the lymphatic system. Technavio’s analysts forecast the Global DLBCL Therapeutics...
105 pages •
By Infiniti Research Limited
• Oct 2018
About Follicular Lymphoma Follicular lymphoma is a subtype of B-cell non-Hodgkin lymphoma (NHL). It is usually indolent (slow-growing) and the tumor cells grow as groups to form nodules. Symptoms of follicular lymphoma include enlarged lymph nodes, shortness of breath, fever, night sweats, and weight loss. Technavio’s...
United States Proton Therapy Market, Patients by 14 Cancer Types (Central Nervous System Tumors, Intraocular Melanomas Cancer, Pituitary Neoplasms Cancer, Base of Skull / Axial Skeleton Cancer, Head and Neck Cancer, Lung Cancer, Retroperitoneal Sarcoma Cancer, Pediatric Cancer Cases (Up to Age 18), Gastrointestinal Tract Cancer, Urinary...
DelveInsight’s ‘Neuroblastoma (NB)- Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of HSV infections in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. Geography Covered • The United States • EU5...
Japan Proton Therapy Market, Patients by 10 Cancer Types (Central Nervous System (CNS), Head and Neck, Lung, GI (Gastro-Intestinal), Hepatocellular Carcinoma (HCC), Pancreas, Gynecologic, Prostate, Bone and Soft Tissue, Others) Reimbursement Policies & Persons Treated at Centers Japan Proton Therapy Market has...
DelveInsight’s ‘Cutaneous T-cell lymphoma (CTCL) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CTCL in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. The...